Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage by respiratory pathogens among Greenlandic children

Johan Emdal Navne, Anders Koch, Hans-Christian Slotved, Mikael Andersson, Mads Melbye, Karin Ladefoged and Malene Børresen

Department of Pediatrics, Hvidovre Hospital, Kettegård allé 30, 2650 Hvidovre, Denmark

ABSTRACT

Background: In 2010, Greenland introduced the 13-valent pneumococcal conjugate vaccine (Prevnar 13®—PCV-13) in the childhood immunisation program. The authors aimed to evaluate the impact of PCV-13 on nasopharyngeal carriage of bacteria frequently associated with respiratory infections in children.

Method: In 2013 a cross-sectional population-based study of nasopharyngeal carriage was conducted among Greenlandic children aged 0–6 years and results were compared with an equivalent study from 2011. Nasopharyngeal swab samples were tested for Streptococcus pneumoniae, non-typeable Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus. Pneumococcal serotyping was performed by Quellung reaction and serotype-specific antisera. Statistical analysis included logistic regression models, adjusting for known risk factors.

Result: A total of 377 nasopharyngeal samples were collected. Overall carriage rate of S. pneumoniae remained unchanged from 2011 to 2013 (51% and 56%, p=0.13), but significant serotype shifts were observed among both vaccinated and unvaccinated children with marked reductions in carriage of vaccine-type pneumococci, counterbalanced by increasing carriage of non-vaccine types. Carriage rate of S. aureus decreased significantly among vaccinated children whereas that of M. catarrhalis increased.

Conclusion: PCV-13 introduction in Greenland is associated with significant changes in nasopharyngeal bacterial carriage. Continued surveillance is warranted to clarify whether these changes are persistent, and affect the pattern of respiratory and invasive diseases in Greenland.

INTRODUCTION

The Inuit population of Greenland suffers from high rates of respiratory infections and invasive bacterial diseases [1], causing higher morbidity and mortality than among non-Inuit [1–7].

Nasopharyngeal bacterial carriage is the essential precursor of these infections with Streptococcus pneumoniae, non-typeable Haemophilus influenzae (NTHi), Moraxella catarrhalis, and Staphylococcus aureus as the most clinically relevant bacteria [8–11]. Besides being a source of respiratory infections, nasopharyngeal colonisation is also a source of transmission to other individuals. Greenlandic children are frequently colonised by these agents, with acquisition shortly after birth and frequent co-colonisation by multiple species [12]. The disease burden from respiratory tract infections in Greenlandic children is among the highest reported [4], primarily in the form of acute and chronic otitis media with frequent long-term sequelae [13]. The Inuit populations of Alaska and Canada share the high risk of respiratory infections as well as invasive pneumococcal disease (IPD) [2,14,15]. In Greenland, Inuit have four times as high risk of invasive pneumococcal disease compared with non-Inuit [16].

The 7-valent pneumococcal conjugate vaccine (Prevnar 7®; Pfizer/Wyeth (PCV-7)), introduced in the childhood immunisation program in 2000 in the US and gradually widespread in many countries, has proven efficient in reducing disease rates caused by the 7 serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F and 23F), so-called vaccine types (PCV-7 VT) [17]. Furthermore, the PCV-7 has proven to be able to prevent PCV-7 VT nasopharyngeal carriage and thus interrupt the chain of transmission to other individuals including non-vaccinated persons, resulting in herd immunity [18]. However, the overall effect on pneumococcal carriage rates has been somewhat counterbalanced by increasing rates of pneumococcal serotypes.
not included in the vaccine (non-vaccine types: PCV-7 NVT), a phenomenon known as replacement [17,19,20]. Recent studies indicate that the carriage rates of other co-colonising pathogens such as S. aureus and NTHi may also be changed after PCV introduction [18,21]. These observations have subsequently raised the concern of an altered disease pattern after widespread use of PCV, given the polymicrobial pathogenesis of respiratory diseases. Thus, in a randomised controlled trial from Finland, higher rates of acute otitis media (AOM) caused by NTHi were observed among PCV-7 vaccinated children compared with a control group of unvaccinated children [22]. Also, S. aureus-related AOM has been observed in higher proportions among those who are PCV-7 vaccinated [23]. A possible mechanism for the observed changes may be the dynamic nature of the nasopharyngeal microbial composition, where the balance may be skewed due to a PCV-related clearance of vaccine-type (VT) pneumococci which leaves the nasopharyngeal niche vacant to be occupied by other opportunistic microbes [24].

In 2000 the PCV-7 was introduced in the childhood immunisation program in Alaska. In the following years the overall incidence rate of IPD in the total childhood population of Alaska was reduced, but among native Alaskans, a dramatic increase in IPD rates caused by non-vaccine types (NVT) resulted in an even bigger disparity in IPD rates between the Native Alaskan and the general US population [25]. In 2010 in Alaska the PCV-7 was replaced by the 13-valent pneumococcal conjugate vaccine (PCV-13). This resulted in further reductions in IPD rates, particularly those caused by PCV-13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F), but also in rates of IPD caused by non-PCV-13 serotypes [26]. However, the decrease in non-PCV-13 IPD rates may not be sustained, as a carriage study from 2014 in Alaskan natives found increasing rates of non-PCV-13 carriage in the years after PCV-13 introduction [27].

Greenland introduced PCV-13 (Prevnar 13®; Pfizer/Wyeth) in the childhood immunisation program in September 2010 [28]. We aimed to describe possible changes in nasopharyngeal carriage rates by four clinically important bacteria among Greenlandic children aged 0–6 years from 2011 to 2013 following the introduction of PCV-13 in Greenland.

Methods

We conducted a cross-sectional carriage study from October to December 2013 and compared results with those from a previous cross-sectional study conducted between October and December 2011 [12]. Since 1972 all citizens of Greenland have been given a unique personal identification number registered in the Civil Registration System (CRS). The daily updated CRS contains vital information about date and place of birth, gender, birth order, siblings, parents, and current and earlier addresses [29]. The unique personal identification number allows for accurate linkage between all national registers. Through the CRS registry, we identified all children aged 0–6 years living, in October 2013, in the towns of Tasilaq (East Greenland) or Sisimiut (West Greenland) including their surrounding settlements, and invited the children via their parents to participate. After giving informed consents, parents or caretakers completed a questionnaire with help from an interpreter regarding birthplace, number of siblings, day-care institution attendance, recent antibiotic use, domestic tobacco exposure, recent respiratory tract infections (otitis media, tonsillitis, pneumonia or ear-discharge within the last 3 months or rhinitis within the last week), hospitalisations within the last 3 months, number of rooms in the household exclusive of bathroom and kitchen, and number of children less than 5 years sleeping in the same room. Ethnicity was based on the parents’ place of birth. If both parents were born in Greenland, ethnicity was defined as Inuit; one parent born in Greenland and one elsewhere or unknown was defined as a “mixed Inuit”, and no known parents born in Greenland as “other”, which is mainly Danish (Caucasian) ethnicity. Data on PCV-13 doses were obtained from local medical files. The PCV-13 is administered as a 2+1 schedule given at 3 and 5 months of age, with a booster at 12 months of age. During the introduction of the vaccine, a catch-up campaign was initiated, offering three vaccinations for children aged 3–11 months, and two vaccinations for children aged 12–23 months [28].

Ethical approval

The study fulfilled the Helsinki II Declaration and was scientific ethically approved by the Greenlandic Scientific Commission (Journal no. 2011 – 056257, doc. no. 738293, Journal no. 2012 – 060783, doc.no. 821618) and the Danish Data Protection Agency (2008 – 54-0427).

Nasopharyngeal sampling

Children were sampled at the local day-care institutions and schools or invited to the health-care centre to participate. Briefly, the World Health Organisation protocol for pneumococcal carriage studies [30] was followed, sampling from the posterior nasopharynx with Minitip Flocked Nylon Swabs (FLOQSwabs™, Copan, Italy) and using Skim milk-Tryptone-Glucose-Glycerin medium (STGG), which has proven useful for the study
of respiratory pathogens including *S. pneumoniae*, NTHi and *M. catarrhalis* [31]. Samples were temporarily stored (up to 3 weeks) at −20°C before shipping to Denmark for storage at −80°C. We used the same procedure as was used in the study from 2011 [12].

**Laboratory analysis**

Swab samples were thawed and tested at Statens Serum Institut (SSI), Copenhagen, Denmark, for the presence of *S. pneumoniae*, NTHi, *M. catarrhalis* and *S. aureus* using standard culture methods. Bacterial identification was based on colony morphology by conventional microbiologic procedures and verified by MALDI/TOF mass spectrometry [32].

Pneumococci were identified based on α-hemolysis, optochin sensitivity and capsular reaction (Quellung). Non-typeable pneumococci were identified using a bile solubility test. Pneumococcal group-determination was performed directly on the serum-broth-enriched nasopharyngeal samples by Pneumotest latex*®* (SSI, Denmark) agglutination and serotypes identified with Quellung [33] reaction by the use of type-specific antisera from SSI [34,35]. To increase the likelihood of detecting low-density carriage and multiple pneumococcal serotype carriage, we added 50 µl of the nasopharyngeal swab samples to a 2 ml serum-ox broth and incubated in CO₂, 37°C for 24 hours, before plating. This has previously been shown to increase the detection level of *S. pneumoniae* in nasopharyngeal swab samples [35].

*M. catarrhalis* was isolated from chocolate-agar plates containing antibiotics (Polymyxin B (27246 IE), Lincomycin (0.001 gr), Amphotericin B (0.002 gr) and Trimethoprim (0.003 gr)) to inhibit the growth of most Gram-positive and Gram-negative bacteria as well as fungal species. We identified the bacteria by their morphology and typical characteristics of *M. catarrhalis*, such as being able to slide the colonies along the agar surface without disrupting them (“the Hockey-puck sign”). *S. aureus* were isolated from blood-agar plates by their morphologic appearance (yellow or white colonies) and tested with a catalase test and if positive by coagulase testing using Staphaurex Plus® (OXOID). Subsequently the different species were verified by MALDI/TOF.

**Statistical analyses**

The study was designed to demonstrate potential changes in pneumococcal carriage after the introduction of the PCV-13 as the primary outcome, and changes in NTHi, *M. catarrhalis* and *S. aureus* as secondary outcomes. Based on the most recent figures from Greenland in 1996 [36], carriage rates in children aged 0–7 years were estimated to be 67, 42 and 8% for NTHi, *M. catarrhalis* and *S. aureus*, respectively. Given these estimates sample sizes of 350 in each of the 2 years (2011 and 2013) would be sufficient to detect a minimal difference in carriage between the years of 10, 11 and 7%, with 80% power and a significance level of 5%. Differences in carriage rates were tested by chi-square tests, with a p-value <5% considered significant. Associations between nasopharyngeal carriage of the four bacteria and PCV-13 vaccination status were estimated by multivariable logistic regression analyses. Possible confounders were tested separately in a basic model adjusted for age (1-year intervals), sex, PCV-13 vaccination status and sampling-year. A final multivariate model was constructed by including all possible confounders significant in the basic models. This included age, sex, PCV-13 vaccination status, sampling-year, ethnicity, region (East/West), current day-care attendance, having siblings in day-care and recent respiratory infections. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). For analytical purposes we grouped pneumococcal serotypes into vaccine types (VT) and non-vaccine types (NVT). In case of potential repeated measurements from individuals appearing in both of the two cross-sectional studies, we did a robustness analysis using a general estimation equation [37] to account for correlated data.

**Results**

A total of 377 children participated in 2013 with demographic characteristics as shown in Table 1. Eighty-six children also participated in the previous cross-sectional study from 2011 [12]. When testing the effect of repeated measurements on bacterial colonisation only minimal changes in estimates and confidence intervals were observed, and the interpretation of results was unchanged. The distribution of most baseline characteristics of the study population in this study was comparable to those of the previous study from 2011 (Table 1). However, significant differences were seen with regard to proportions of the children sampled in East and West Greenland, day-care attendance, in-house smoking and fractions of PCV-13 vaccinated children.

**S. pneumoniae**

The overall carriage rate of pneumococci in 2013 was 56%, and the most frequently identified serotypes
were 6B, 11A, 15A, 15B, 21, 23A, 23B, 23F, 35B and 35F (Figure 1). In 2013, the overall pneumococcal carriage rate was basically unchanged compared with 2011 (Table 1). However, among PCV-13 vaccinated children carriage rates of VT pneumococci were significantly reduced (adjusted odds ratio (aOR) 0.43, 95% confidence interval (CI): 0.20–0.90) and carriage rates of NVT were significantly increased (aOR 1.63, 95% CI: 1.07–2.48) compared with unvaccinated children. Furthermore, when adjusting for PCV-13 vaccination, odds of carrying VT in 2013 were significantly reduced compared with 2011 (aOR 0.44, 95% CI: 0.24–0.82) whereas odds of NVT carriage were increased (aOR 1.36, 95% CI: 0.97–1.90) (Table 2). The reduction in VT carriage and increase in NVT carriage were predominantly seen among children aged 1–4 years, the group with greatest difference in vaccination rate (Figure 2(a)).

**NTHi**

The average carriage rate among children <3 years was 47% (95% CI: 42–53%), and 40% (95% CI: 35–45%) among children ≥3 years. Overall, NTHi carriage remained stable during the period (Table 1, Figure 2).

---

**Table 1.** Demographic characteristics of study population 2013 (n=377 children) and the population from a comparable cross-sectional study in 2011 (n=352) [12].

| Variable                        | Level | Year 2013 n=377 (%) | Year 2011 n=352 (%) | p* |
|---------------------------------|-------|---------------------|---------------------|----|
| Gender                          | Male  | 192 (51)            | 181 (51)            | 0.98 |
| Age, years                      | Median (Q1;Q3) | 3.50 (1.68; 5.12) | 2.85 (1.08; 4.84) | 0.34 |
| Ethnicity                       | Inuit | 343 (91)            | 324 (91)            | 0.35 |
| Region of Greenlandb            | East-coast | 186 (49)         | 122 (35)            | <0.001 |
| Day-care attendance (current)   | +     | 232 (62)            | 258 (73)            | <0.001 |
| Having siblings in DCc          | +     | 134 (36)            | 137 (39)            | 0.29 |
| In-house smokinga               | +     | 39 (10)             | 83 (24)             | 0.002 |
| Sharing bedroom with children <5 years of age | + | 210 (56) | 210 (60) | 0.45 |
| Number of persons per roomd     | 0     | 23 (6)              | 14 (4)              | 0.41 |
|                                | 1     | 181 (48)            | 167 (47)            |     |
|                                | 2     | 167 (44)            | 163 (46)            |     |
| Respiratory infection <3 monthsf | +    | 229 (61)            | 206 (59)            | 0.43 |
| Antibiotics <3 monthsg          | +    | 53 (14)             | 58 (16)             | 0.39 |
| PCV-13 vaccinatedh              | +    | 212 (56)            | 130 (37)            | <0.0001 |
| S. pneumoniae detected          | +    | 212 (56)            | 178 (50)            | 0.13 |
| VT pneumococci detected         | +    | 18 (5)              | 44 (12)             | <0.001 |
| NVT pneumococci detected        | +    | 185 (49)            | 137 (38)            | 0.003 |
| S. aureus detected              | +    | 29 (8)              | 41 (12)             | 0.04 |
| NTHi detected                   | +    | 168 (45)            | 152 (43)            | 0.54 |
| M. catarrhalis detected         | +    | 183 (49)            | 188 (53)            | 0.38 |
| Any of the bacteria detectedi   | +    | 317 (84)            | 290 (82)            | 0.55 |

**Abbreviations:** DC: day-care centre; PCV-13: the 13-valent pneumococcal conjugate vaccine; S. pneumoniae: Streptococcus pneumoniae; VT pneumococci: pneumococcal serotypes included in the PCV-13; NVT pneumococci: pneumococcal serotypes not included in the PCV-13; S. aureus: Staphylococcus aureus; NTHi: non-typeable Haemophilus influenzae; M. catarrhalis: Moraxella catarrhalis. 

a. p-Value based on chi-square test for difference. Significant findings (p<0.05) in bold
b. Region: East (Tasiilaq, Kuummiut, Sermiligaaq, Kulusuk), West (Sisimiut, Sarfannguaq).
c. Having siblings attending a day-care institution.
d. Tobacco smoking inside the house.
e. Average number of persons per room: (0=less than 1 person per room in household), (1=1 to <2 persons per room), (2=≥2 persons per room), missing n=8 (2011) n=6 (2013).
f. Respiratory infections: any episode of rhinitis, acute otitis media, ear-discharge, tonsillitis or pneumonia within the last 3 months prior to nasopharyngeal sampling.
g. Having received treatment with antimicrobial drugs within the last 3 months.
h. PCV-13 vaccinated: vaccinated with ≥1 dose of the 13-valent pneumococcal conjugate vaccine.
i. Any bacteria: the detection of S. pneumoniae, M. catarrhalis, NTHi or S. aureus in the nasopharyngeal sample.
Table 2. Crude and adjusted odds ratios for bacterial nasopharyngeal carriage by *Streptococcus pneumoniae*, non-typeable *Haemophilus influenzae*, *Moraxella catarrhalis* or *Staphylococcus aureus* among Greenlandic children aged 0–6 years in 2013 compared with data from a cross-sectional study in 2011 [12].

| Bacterium | PCV-13 Year | No (ref.) | OR* (95% CI) | aORb (95% CI) | p | 2011 (ref.) | OR* (95% CI) | aORb (95% CI) | p |
|-----------|-------------|-----------|--------------|---------------|---|-------------|--------------|---------------|---|
| *S. pneumoniae* | 1 (ref.) | 1.31 (0.88–1.95) | 1.19 (0.78–1.82) | 0.41 | 1 (ref.) | 1.23 (0.90–1.68) | 1.18 (0.84–1.65) | 0.33 |
| VT | 1 (ref.) | 0.44 (0.22–0.92) | 0.43 (0.20–0.90) | 0.02 | 1 (ref.) | 0.42 (0.23–0.75) | 0.44 (0.24–0.82) | 0.01 |
| NVT | 1 (ref.) | 1.65 (1.11–2.46) | 1.63 (1.07–2.48) | 0.02 | 1 (ref.) | 1.45 (1.06–1.99) | 1.36 (0.97–1.90) | 0.07 |
| NTHi | 1 (ref.) | 1.17 (0.78–1.75) | 1.29 (0.84–1.98) | 0.24 | 1 (ref.) | 1.07 (0.78–1.48) | 1.10 (0.79–1.54) | 0.58 |
| *M. catarrhalis* | 1 (ref.) | 1.72 (1.14–2.58) | 1.52 (0.99–2.33) | 0.06 | 1 (ref.) | 1.83 (1.06–1.16) | 0.82 (0.58–1.16) | 0.27 |
| *S. aureus* | 1 (ref.) | 0.51 (0.27–0.94) | 0.48 (0.25–0.91) | 0.03 | 1 (ref.) | 0.70 (0.42–1.18) | 0.62 (0.35–1.07) | 0.09 |
| Any bacterium | 1 (ref.) | 1.58 (0.88–2.84) | 1.43 (0.76–2.68) | 0.27 | 1 (ref.) | 1.13 (0.74–1.74) | 1.04 (0.65–1.66) | 0.87 |

**Abbreviations:** PCV-13: the 13-valent pneumococcal conjugate vaccine; OR: odds ratio; aOR: adjusted odds ratio; p: p-value for aOR; CI: confidence interval; *S. pneumoniae*: Streptococcus pneumoniae; VT: pneumococcal serotypes included in the 13-valent pneumococcal conjugate vaccine; NVT: pneumococcal serotypes not included in the 13-valent pneumococcal conjugate vaccine; NTHi: non-typeable *Haemophilus influenzae*; *M. catarrhalis*: *Moraxella catarrhalis*; *S. aureus*: *Staphylococcus aureus*; Any bacterium: odds of carrying *S. pneumoniae*, NTHi, *M. catarrhalis* or *S. aureus* (grouped).

a. Odds ratios mutually adjusted for year of sampling and PCV-13 vaccination, as well as age groups (1 year intervals) and sex.
b. Additional adjustments: region (East/West Greenland), recent respiratory infection (otitis media, ear-discharge, nasopharyngitis, tonsillitis or pneumonia within the last 3 months), current day-care attendance (yes/no), having siblings in a day-care (yes/no) and ethnicity (“Inuit”, “mixed Inuit/other ethnicity” or “non-Inuit”).
c. Significant findings (p<0.05) in bold.

**M. catarrhalis**

Average carriage rate among children <3 years was 66% (95% CI: 61–71%) and 37% (95% CI: 32–41%) among children ≥3 years. Overall carriage rates were unchanged during the period (53% vs. 49%) (Table 1, Figure 2). In the crude analysis PCV-13 vaccination was associated with increased odds of *M. catarrhalis* carriage OR 1.72 (95% CI: 1.14–2.58), and when adjusted for confounders the association was attenuated although still indicating a positive association (aOR 1.52, 95% CI: 0.99–2.33).

**S. aureus**

Among children less than 3 years average carriage rate was 12% (95% CI: 8–15%) and among children ≥3 years 8% (95% CI: 6–11%). Among vaccinated children there was a significant reduction in carriage rate of *S. aureus* (Table 2, Figure 2).

**Discussion**

In line with previous PCV-7 carriage studies we found a substantial pneumococcal serotype shift from VT to NVT among vaccinated individuals 3 years after PCV-13 introduction in Greenland. In a double-blind randomised placebo-controlled trial, Obaro et al. [38] were among the first to report significant reductions in carriage rates of vaccine serotypes in Gambian infants vaccinated with a pentavalent PCV, counterbalanced by increasing carriage rates of NVT. In the following years several studies have confirmed these findings [24]. In our study we also observed a cohort effect showing reductions in VT carriage independent of PCV-13 vaccination, which may indicate herd immunity. Parallel to this, NVT carriage rates increased from 2011 to 2013 independently of PCV-13 vaccination. Besides the pneumococcal serotype shift, significant changes in carriage of other co-colonising clinically important pathogens were observed. *M. catarrhalis* carriage increased among PCV-13 vaccinated children. Natural fluctuations in rates of *M. catarrhalis* circulating in the community may explain this, but bacterial interactions may also be part of the explanation. We have previously reported a positive interaction between *M. catarrhalis* and NVT pneumococci [12]. Increase in NVT carriage following PCV-13 introduction may change the balance between the colonising bacteria in the nasopharynx towards higher carriage rates of *M. catarrhalis*. Whether increasing carriage rates of *M. catarrhalis* lead to changes in disease rates is not clarified. However, studies of PCV-7 impact on AOM have shown increases in proportions of *M. catarrhalis* and NTHi in middle ear fluid from PCV-7 vaccinated children with AOM, compared with non-vaccinated children, indicating an association [39–42]. A scenario of increasing carriage rates of *M. catarrhalis*, being an important oto-pathogen in young children [10], is concerning, especially since the Greenlandic population suffers from a very high burden of otitis media [4].

We also observed a significant reduction in carriage by *S. aureus* among PCV-13 vaccinated children. In a randomised controlled trial of the effect of PCV-7 on nasopharyngeal carriage, Van Gils et al. [43] found a negative association between pneumococci (both PCV-7 serotypes and non-PCV-7 serotypes) and *S.
The mechanism behind this association is unknown, but may include the production of hydrogen peroxide by pneumococci, which in vitro has been shown to eliminate *S. aureus* [44]. We found slightly higher rates of pneumococcal carriage among PCV-13 vaccinated children but the increase was not significant. The reduction in *S. aureus* carriage may also be related to the increase in *M. catarrhalis* carriage, since *S. aureus* and *M. catarrhalis* have previously been shown to be negatively associated [12]. One difference in the detection of *S. aureus* and the other bacteria is that the present study was not designed specifically to sample from the anterior nasal cavity where *S. aureus* resides. However, when entering the nasopharynx, the niche is passed twice, giving the opportunity to detect current *S. aureus* colonisation.

We believe a main strength of this study is the fact that it is based on two consecutive cross-sectional studies using exactly the same design, sampling method, transport medium and laboratory techniques, minimising study design bias. Furthermore, the study is population-based, based on random sampling from the CRS, a register updated on a daily basis minimising selection bias. We made a considerable effort in obtaining valid data from registers and questionnaires on potential confounders for carriage. However, some differences in baseline characteristics between the two cross-sectional studies were present, including proportions of children sampled in the two regions. Since the regions are separated by large distances local clustering in carriage proportions may have biased the results. However, we accounted for this by adjusting for region

---

**Figure 2.** Proportions of PCV-13 vaccinated children by age group and year of sampling (a). Carriage pattern of *S. pneumoniae* (PCV-13 serotypes, non-PCV-13 serotypes) (b,c), *M. catarrhalis* (d), non-typeable *Hemophilus influenzae* (e), and *S. aureus* (f), according to age groups and period. Dotted lines represent results from a previous study conducted in 2011 [12].
in the multivariable analyses. In 2013, the proportions of children attending a day-care centre and children being exposed to in-house smoking were smaller than in 2011. This could have created bias towards overestimating the effect of the vaccine, as both factors have been shown to increase the risk of \( S. \) pneumoniae carriage [45]. We did, however, include these factors in the multivariable analyses to limit the potential confounding effect.

A major limitation to our study was the lack of consistent pre-vaccination baseline data. Approximately one-third of the children had received the first dose of PCV-13 when the first cross-sectional study was conducted, which may have resulted in an underestimation of the direct vaccine effects. When including vaccination status in the multivariate regression analysis, we consistently found significant changes in carriage rates of VT and NVT independent of vaccination status according to the year of sampling (2013 compared with 2011), indicating a herd effect. Since our baseline data included a proportion of vaccinated children, we cannot rule out that the observed changes may to some extent have been biased by early indirect herd immunity effects.

Moreover, since we have only 3 years of study time post-PCV-13 introduction, we are unable to determine whether the observed changes reflect a transitional or steady state.

In conclusion, PCV-13 introduction in Greenland was associated with significant shifts in nasopharyngeal pneumococcal serotype distribution with marked reductions in VT carriage and increased carriage of NVT, while the overall carriage rate of pneumococci was unchanged. Independent of this, a period-specific reduction in carriage rates of vaccine-type pneumococci from 2011 to 2013 indicated a level of PCV-13-induced herd immunity. Furthermore, we found an increase in \( M. \) catarrhalis and reduction in \( S. \) aureus carriage among vaccinated children compared with unvaccinated children. Continued surveillance is warranted to clarify whether these changes are temporary or persist in the long term. It is also essential to monitor the clinical significance of these changes, including the invasive potential of the emerging NVT.

Acknowledgements

The authors would like to give special thanks for the help and hospitality provided by the chief medical doctors at the Hospital of Tasiilaq, Drs. Hans-Christian Florian Sørensen and Ove Rosing Olsen, respectively, as well as the staff at the two hospitals for logistic assistance. The fieldwork would not have been successful without extensive help from the interpreters Susanne Vid Stein and Antoinette Kuitse. A huge effort was made with analysis of nasopharyngeal samples by the technical laboratory staff at Statens Serum Institut, with special thanks to the laboratory workers Kirsten Olsson, Kirsten Burmeister and Monja Hammer and medical student Jacqueline Mistry. The authors are sincerely grateful for the many participating children and their families for spending time with us and giving us the opportunity to fulfil the study. Finally, the authors are very thankful for the friendly help from the public schools and day-care institutions of Sisimiut and Tasiilaq.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the The Commission of Scientific Research in Greenland co-financed by The Danish Research Council [10-0905576].

ORCID

Hans-Christian Slotved http://orcid.org/0000-0002-7294-4911

References

[1] Meyer A, Ladefoged K, Poulsen P, et al. Population-based survey of invasive bacterial diseases, Greenland, 1995–2004. Emerg Infect Dis. 2008;14:76–79.
[2] Bruce MG, Deeks SL, Zulz T, et al. International circumpolar surveillance system for invasive pneumococcal disease, 1999–2005. Emerg Infect Dis. 2008;14:25–33.
[3] Gahm-Hansen B, Aen-Larsen B, Mosgaard L, et al. Respiratory tract infections in Greenland: results of an audit project. Int J Circumpolar Health. 2004;63(Suppl 2):209–213.
[4] Homoe P, Christensen RB, Bretlau P, et al. Acute otitis media and age at onset among children in Greenland. Acta Otolaryngol. 1999;119:65–71.
[5] Koch A, Molbak K, Homoe P, et al. Respiratory tract infections in Greenlandic children: a prospective cohort study. Int J Circumpolar Health. 1998;57(Suppl 1):252–254.
[6] Homoe P, Christensen RB, Bretlau P. Prevalence of otitis media in a survey of 591 unselected Greenlandic children. Int J Pediatr Otorhinolaryngol. 1996;36:215–230.
[7] Christiansen J, Paulsen P, Ladefoged K. Invasive pneumococcal disease in Greenland. Int J Circumpolar Health. 2004;63(Suppl 2):214–218.
[8] O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.
[9] Van Eldere J, Slack MPE, Ladhani S, et al. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis. 2014;14(12):1281–1292.
[10] Verduin CM, Hol C, Fleer A, et al. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev. 2002;15:125–144.
[11] Wertheim HFL, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751–762.
[12] Navne JE, Børresen ML, Slotved H, et al. Nasopharyngeal bacterial carriage among young children in Greenland: a population at high risk of respiratory infections. Epidemiol Infect. 2016;144:3226–3236.

[13] Jensen RG, Homoe P, Andersson M, et al. Long-term follow-up of chronic suppurative otitis media in a high-risk children cohort. Int J Pediatr Otorhinolaryngol. 2011;75:948–954.

[14] Helferty M, Rotondo JL, Martin I, et al. The epidemiology of invasive pneumococcal disease in the Canadian North from 1999 to 2010. Int J Circumpolar Health. 2013;72:1–6.

[15] Ratnesar P. Chronic ear disease along the coasts of labrador and Northern Newfoundland. J Otolaryngol. 1976;5:122–130.

[16] Navne JE, Børresen ML, Slotved HC, et al. Population-based study of incidence, risk factors and mortality from invasive pneumococcal disease in Greenland [unpublished data].

[17] Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.

[18] Spijkerman J, Prevaes SMPJ, van Gils EJM, et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS One. 2012;7:e39730.

[19] O’Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211–1220.

[20] Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis. 2012;54:1765–1773.

[21] Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304–309.

[22] Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis. 2012;55:1673–1676.

[23] Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004;363:1871–1872.

[24] Weenberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–1973.

[25] Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native pneumococcal conjugate vaccine coverage. JAMA. 2007;298:1784–1792.

[26] Singleton RJ, Wenger JD, Klejka JA, et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J. 2013;32:257–263.

[27] Gounder PP, Bruce MG, Bruden DJT, et al. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae—Alaska, 2008–2012. J Infect Dis. 2014;209:1251–1258.

[28] Flemming Stenz Kleist. Chief medical officer - Greenland, Newsletter 2010 – Number 1. 2010. [cited 2010 Nov 1]. Available from: http://naalakkersuisuit.gl/~media/Nanoq/Files/Attached%20Files/Landslaegeembedet/DK/Aarsberetniger%202010/Kapitel%2013%20LandsIgeembedet%20nya%20hedsbreve%20USI%20nr%20201.pdf?%200

[29] Pedersen CB, Gøtzsche H, Møller JO, et al. danish civil registration system. A cohort of eight million persons. Dan Med Bull. 2006;53:441–449.

[30] O’Brien KL, Nohynek H. Report from a WHO working group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J. 2003;22:e1–11.

[31] Kajalainen T, Ruokokoski E, Ukkonen P, et al. Survival of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis frozen in skim milk- treptone-glu- cose-glycerol medium. J Clin Microbiol. 2004;42:412–414.

[32] Carbonnelle E, Mesquita C, Bille E, et al. MALDI-TOF mass spectrometry tools for bacterial identifi cation in clinical microbiology laboratory. Clin Biochem. 2011;44:104–109.

[33] Merrill CW, Gwalney JM, Hendley JW, et al. Rapid identification of pneumococci. Gram stain vs. the quellung reaction. N Engl J Med. 1973;288:510–512.

[34] Slotved H-C, Kaltoft M, Skovsted IC, et al. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). J Clin Microbiol. 2004;42:2518–2522.

[35] Kaltoft MS, Skov Sørensen UB, Slotved H-C, et al. An easy method for detection of nasopharyngeal carriage of multiple Streptococcus pneumoniae serotypes. J Microbiol Methods. 2008;75:540–544.

[36] Homoe P, Prag J, Farholt S, et al. High rate of nasopharyngeal carriage of potential pathogens among children in Greenland: results of a clinical survey of middle-ear disease. Clin Infect Dis. 1996;23:1081–1090.

[37] Park T. A comparison of the generalized estimating equation approach with the maximum likelihood approach for repeated measurements. Stat Med. 1993;12:1723–1732.

[38] Obaro SK, Adegbola RA, Banya WA, et al. Carriage of pneumococci after pneumococcal vaccination. Lancet. 1996;348:271–272.

[39] Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403–409.

[40] Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J. 2004;23:824–828.

[41] Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23:829–833.

[42] Revali K, McCormick DP, Patel J, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics. 2006;117:1823–1829.

[43] Van Gils EJM, Hak E, Veenhoven RH, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One. 2011;6:e20229.

[44] Regev-Yochay G, Dagan R, Raz M, et al. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. JAMA. 2004;292:716–720.

[45] Bogaert D, De GR, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–154.